Reading the tape
NASDAQ: FTRE
Fortrea Holdings Inc.
Healthcare · Biotechnology
Market Cap
$1.15B
52w High
$18.67
52w Low
$3.97
P/E
-1.13
Volume
2.16M
Outstanding Shares
93.50M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 106.58%Revenue (TTM): 1%FCF (TTM): -62.79%P/FCF: 44th pct
What changed
The stock rose 106.58% over the last year. Revenue grew 1% over the trailing twelve months. Operating margin moved from -6% to -19.76%. Free cash flow declined 62.79% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -19.76%. A decisive move in revenue — currently up 1% — would be the clearest signal to resolve the ambiguity.
Company profile
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
CEOAnshul Thakral
SectorHealthcare
IndustryBiotechnology
Employees15,000
IPO dateJun 20, 2023
Valuation
Forward P/E—
EV/EBITDA-1.80
Enterprise value$1.47B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-5.24%
Gross margin16.35%▼21.08%vs FY2024
Operating margin-19.76%▲81.29%vs FY2024
ROE-175.01%▼625.84%vs FY2024
Analyst consensus
RatingHold
Target price$18.83▲53.71%
5
Buy
6
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $0.03 · Revenue est $627.42M
View